Use of compound as CYP2E1 inhibitor

1 . A method of inhibiting a CYP2E1, comprising: using one or more compounds or a salt thereof as a CYP2E1 inhibitor to inhibit the CYP2E1, wherein the one or more compounds or a salt thereof target and bind to the CYP2E1, and the one or more compounds are selected from the group consisting of

2 . The method according to claim 1 , comprising:

using at least one selected from the group consisting of the following compounds as the CYP2E1 inhibitor to inhibit the CYP2E1, wherein the at least one selected from the group consisting of the following compounds targets and binds to the CYP2E1:

3 . The method according to claim 1 , wherein the compound reacts with an acid to obtain an acid salt of the compound as the CYP2E1 inhibitor to inhibit the CYP2E1; and

the acid is at least one selected from the group consisting of an inorganic acid and an organic acid;

wherein the inorganic acid is at least one selected from the group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; and

the organic acid is at least one selected from the group consisting of acetic acid, oxalic acid, succinic acid, tartaric acid, malic acid, lactic acid, methanesulfonic acid, p-toluenesulfonic acid, citric acid, resin acid, maleic acid, fumaric acid, salicylic acid, and acetylsalicylic acid;

wherein the compound has a structural formula of

 an X-ray powder diffraction (XRPD) pattern of a first crystal form of a hydrochloride of the compound comprises 3 or more 2θ values selected from the group consisting of 8.4±0.2°, 13.1±0.2°, 14.8±0.2°, 16.6±0.2°, 24.1±0.2°, 27.2±0.2°, 30.5±0.2°, 31.8±0.2°, 33.5±0.2°, 35.4±0.2°, and 35.7±0.2°; and

a differential scanning calorimetry-thermogravimetric analyzer (DSC-TGA) pattern of the first crystal form of the hydrochloride of the compound comprises a significant endothermic peak at 70° C. to 220° C. and shows a thermal decomposition at 80° C. to 170° C.; and

an XRPD pattern of a second crystal form of a sulfate of the compound comprises 5 or more 2θ values selected from the group consisting of 10.1±0.2°, 15.1±0.2°, 16.0±±0.2°, 16.7±0.2°, 19.2±0.2°, 19.9±0.2°, 23.4±0.2°, 24.0±0.2°, 25.8±0.2°, 26.5±0.2°, 28.9±0.2°, 30.3±0.2°, and 32.2±0.2°; and

a DSC-TGA pattern of the second crystal form of the sulfate of the compound comprises at least one endothermic peak at 30° C. to 85° C., 90° C. to 160° C., or 215° C. to 330° C. and shows a thermal decomposition at 150° C. to 350° C.

4 . The method according to claim 1 , wherein a method for preparing the compound as the CYP2E1 inhibitor at least comprises one selected from the group consisting of the following methods:

method 1: subjecting a raw material comprising a compound selected from the group consisting of compounds with a structural formula shown in formula II, a first aprotic solvent, and a Grignard reagent to a first reaction at −20° C. to 25° C. for 0.5 h to 3 h to obtain a first CYP2E1 inhibitor,

wherein the first CYP2E1 inhibitor is at least one selected from the group consisting of compounds with a structural formula shown in formula III:

method 2: subjecting a compound with a structural formula shown in formula III and a hydroxylamine hydrochloride to a second reaction in a presence of a first alkali source to obtain a second CYP2E1 inhibitor,

wherein the second CYP2E1 inhibitor is at least one selected from the group consisting of compounds with a structural formula shown in formula III-1:

method 3: subjecting the compound with the structural formula shown in formula III and an aromatic aldehyde compound to a third reaction at 25° C. to 100° C. for 2 h to 8 h in a presence of a second alkali source to obtain a third CYP2E1 inhibitor,

wherein the third CYP2E1 inhibitor is at least one selected from the group consisting of compounds with a structural formula shown in formula III-2:

 and

method 4: subjecting the compound with the structural formula shown in formula III, an amine compound, and a reducing agent to a fourth reaction in a presence of a first acid source to obtain a fourth CYP2E1 inhibitor,

wherein the amine compound is at least one selected from the group consisting of phenylamine and benzylamine; and

the fourth CYP2E1 inhibitor is at least one selected from the group consisting of compounds with a structural formula shown in formula III-3:

wherein in each of formula II, formula III, formula III-1, formula III-2, and formula III-3, R 1 is one selected from the group consisting of hydrogen, C 1 -C 10 alkyl, and epoxyalkyl: R 3 is at least one selected from the group consisting of hydrogen, C 1 -C 10 alkyl, and a second substituted C 1 -C 10 alkyl.

5 . The method according to claim 4 , wherein in the method 1, the first aprotic solvent is at least one selected from the group consisting of tetrahydrofuran (THF) and diethyl ether and the Grignard reagent is at least one selected from the group consisting of methylmagnesium bromide and methylmagnesium chloride;

in the method 2, the first alkali source is at least one selected from the group consisting of potassium hydroxide, sodium hydroxide, sodium carbonate, pyridine, triethylamine (TEA), and N,N-diisopropylethylamine (DIPEA);

in the method 3, the second alkali source is at least one selected from the group consisting of sodium hydroxide, potassium hydroxide, potassium tert-butoxide, sodium methoxide, and potassium fluoride; and

the aromatic aldehyde compound is at least one selected from the group consisting of p-methoxybenzaldehyde, o-methoxybenzaldehyde, m-methoxybenzaldehyde, p-chlorobenzaldehyde, o-chlorobenzaldehyde, m-chlorobenzaldehyde, p-phenylbenzaldehyde, p-isopropylbenzaldehyde, and 3,4-difluorobenzaldehyde; and

in the method 4, the first acid source is at least one selected from the group consisting of formic acid, acetic acid, and hydrochloric acid; and

the reducing agent is at least one selected from the group consisting of sodium cyanoborohydride, sodium borohydride, and lithium aluminum hydride (LAH);

wherein in the method 1, a molar ratio of the compound selected from the group consisting of compounds with the structural formula shown in formula II to the Grignard reagent is 1:1 to 1:3;

in the method 2, a molar ratio of the compound with the structural formula shown in formula III to the hydroxylamine hydrochloride is 1:1 to 1:6;

in the method 3, a molar ratio of the compound with the structural formula shown in formula III to the aromatic aldehyde compound is 1:1 to 1:5; and

in the method 4, a molar ratio of the compound with the structural formula shown in formula III to the reducing agent is 1:1 to 1:5.

6 . The method according to claim 4 , wherein the compound selected from the group consisting of compounds with the structural formula shown in formula II is prepared through the following process:

subjecting a raw material comprising a compound selected from the group consisting of compounds with a structural formula shown in formula II-1, a condensing agent, N,O-dimethylhydroxylamine hydrochloride, and a second aprotic solvent to a fifth reaction at 20° C. to 60° C. for 10 h to 20 h in a presence of a third alkali source to obtain the compound selected from the group consisting of compounds with the structural formula shown in formula II,

wherein the condensing agent is at least one selected from the group consisting of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, didodecyl carbonate, N,N-carbonyldiimidazole, dicyclohexylcarbodiimide, and N-(4-carboxyphenyl) maleimide (CPMI); and

the third alkali source is at least one selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, pyridine, TEA, and DIPEA;

wherein the compound selected from the group consisting of compounds with a structural formula shown in formula II-1, the condensing agent, and the N,O-dimethylhydroxylamine hydrochloride are in a molar ratio of 1:1:1 to 1:5:5;

a preparation of the compound selected from the group consisting of compounds with a structural formula shown in formula II-1 at least comprises the following steps:

subjecting a raw material comprising a compound selected from the group consisting of compounds with a structural formula shown in formula II-2 to a hydrolysis in a presence of a fourth alkali source to obtain a mixture, and adjusting a pH of the mixture with a second acid source to 2 to 3 to obtain the compound selected from the group consisting of compounds with a structural formula shown in formula II-1,

wherein the fourth alkali source is at least one selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, and potassium carbonate;

wherein the second acid source is a concentrated hydrochloric acid; and

the adjusting the pH of the mixture with the second acid source to 2 to 3 is conducted at 10° C. to 50° C.;

wherein a preparation method of an acid salt of the compound at least comprises:

subjecting a material comprising the compound and a solvent to a sixth reaction at −20° C. to 80° C. for 0.5 h to 10 h to obtain the acid salt of the compound;

wherein the solvent is at least one selected from the group consisting of an ether compound, an alcohol compound, an ester compound, a nitrile compound, a ketone compound, a haloalkane, an alkane, and an aromatic hydrocarbon;

wherein in each of formula II-1 and formula II-2, R 1 is one selected from the group consisting of hydrogen, C 1 -C 10 alkyl, and epoxyalkyl: R 3 is at least one selected from the group consisting of hydrogen, C 1 -C 10 alkyl, and a second substituted C 1 -C 10 alkyl.

7 . The method according to claim 1 , wherein the CYP2E1 inhibitor is used in an active ingredient of a drug for treating or preventing an inflammation-mediated disease (IMD); and the IMD comprises at least one selected from the group consisting of a liver cancer, a glioma, an ovarian cancer, a lung cancer, a bladder cancer, a gallbladder cancer, a liver damage, a fatty liver, a hepatitis, a liver fibrosis, a pulmonary fibrosis, a rheumatic and rheumatoid arthritis, a sepsis, an Alzheimer's disease (AD), an ischemic stroke, a Parkinson's disease (PD), a hyperlipidemia, an atherosclerosis (AS), a coronary heart disease (CHD), and a diabetes.